Nearly 6.7 million adults in the U.S. have heart failure, with prevalence expected to rise to 8.5 million by 20301,2. While heart failure is a chronic, progressive disease, advances in technology are ...

The CardioMEMS HF System is proven to significantly reduce heart failure hospitalizations and improve quality of life in NYHA class III HF patients St. Jude Medical now intends to exercise its ...

Abbott Laboratories ABT recently gained FDA approval of an expanded indication for its CardioMEMS HF System to support the care of heart failure patients. The CardioMEMS HF System has been found to ...

(RTTNews) - Abbott (ABT) said that the U.S. Food and Drug Administration has approved an expanded indication for the company's CardioMEMS HF System to support the care of more people living with heart ...

Abbott Laboratories’ Cardiomems heart failure (HF) system is open to a larger patient population following an expanded approval from the FDA. Abbott’s system had previously been approved for class III ...

The US Food and Drug Administration (FDA) has expanded the indication for Abbott's CardioMEMS heart failure (HF) system, making an additional 1.2 million patients in the United States eligible for the ...

ATLANTA, Aug. 26 -- CardioMEMS, Inc., a medical technology company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body, today ...

GAITHERSBURG, MD (updated) — A Food and Drug Administration (FDA) advisory committee narrowly voted in favor of a novel device that measures pulmonary-artery (PA) pressures in patients with heart ...

Please provide your email address to receive an email when new articles are posted on . Abbott announced its sensor providing hemodynamic-guided management of patients with HF has received an expanded ...